Dr. Ramiro Garzon, MD

Dr. Garzon practices at SageWest Riverton in Riverton, Wyoming, part of ScionHealth.

Dr. Garzon's NPI, 1851491468, was assigned on September 24, 2006. Dr. Garzon graduated from Universidad Nacional de Cordoba in 1994. Dr. Garzon's Ohio license number on file is 35088651.

Dr. Garzon's primary practice is SageWest Riverton, at 2100 W Sunset Dr, Riverton, WY 82501 in Fremont County. The practice phone is (307) 856-4161.

Dr. Garzon's primary practice is SageWest Riverton in Riverton, Wyoming, part of ScionHealth. Dr. Garzon is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Garzon to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Garzon practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Garzon's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Garzon is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Garzon's licenses on file in 3 states: Ohio, Utah and Pennsylvania.

Dmand AI lists chronic anemia, chronic leukemia and multiple myeloma among the conditions Dr. Garzon treats.

CMS data shows 301 Medicare services from Dr. Garzon across 3 procedure codes in 2024, for 32 Medicare patients. Medicare paid $12,075 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 32 Medicare patients who saw Dr. Garzon in 2024. The largest group is 65 to 74, with 18 patients. 75% of them have high blood pressure, and 66% have high cholesterol. Their average risk score is 2.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Garzon's median patient age at 72, with 35% women.

In 2024, Dr. Garzon wrote 183 Medicare Part D claims for 14 patients. 78% of them were for generic drugs. CMS names the drug for 114 of them, across 5 drugs with 11 or more claims each, at $28,509 in total drug cost. In 2023, CMS named 52 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Garzon for performance year 2024, reported as part of a group. Dr. Garzon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Garzon as offering telehealth.

Dmand AI links 96 papers to Dr. Garzon, published from 2006 to 2024. 2016 was the busiest year, with 7. The most frequent topics are Leukemia, Myeloid, Acute, MicroRNAs and Cell Line, Tumor. Dr. Garzon has published most often in Blood. Dr. Garzon's most frequent co-authors are John C. Byrd, MD, Michael A. Caligiuri, MD and Alison R. Walker, MD.

Dmand AI links Dr. Garzon to 4 clinical trials, 3 of them phase 1 studies. Conditions studied include Leukemia, Myeloid, Acute, Congenital Abnormalities and Myelodysplastic Syndromes. Alison Walker sponsors the most, 2.

CMS Open Payments shows 6 general payments to Dr. Garzon from 1 drug or device company in 2016. Consulting fees make up the largest share, 86% of the total. Novartis Pharmaceuticals Corporation paid the most, $6,753.

Dr. Garzon graduated from Universidad Nacional de Cordoba in 1994.

Dr. Garzon is in network with 6 carriers, including Cigna, United Healthcare and Alliant Health Plans. PPO plans come from the most carriers, 4. Check the plan with the practice before a visit.